You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加速生物藥商業化佈局!博安生物授權阿斯利康在中國特定縣域市場獨家推廣博優諾®
格隆匯 05-27 08:00

綠葉製藥集團(02186.HK)於5月26日宣佈,其控股子公司博安生物與阿斯利康中國圍繞抗腫瘤生物藥博優諾®(貝伐珠單抗注射液)的商業化權益簽署協議,授權後者在中國21個省市及自治區的縣域地區獨家推廣博優諾®

簽約儀式
左:博安生物首席執行官 姜華
右:阿斯利康中國副總裁、及縣業務負責人 杜浩晨

此次合作的達成基於雙方在中國各級市場的資源互為整合:博安生物通過自有的業務團隊、商業化資源和網絡,積極提升核心市場的患者用藥可及性;同時,為了進一步加大博優諾®的患者覆蓋,博安生物聯合阿斯利康,藉助其在中國縣域深耕多年所積累的廣闊的市場覆蓋及渠道拓展能力,推動該產品進一步惠及更多患者人羣。

博優諾®是由博安生物自主開發的生物抗體藥物。該產品於近期獲得中國國家藥品監督管理局的上市批准,用於治療晚期、轉移性或複發性非小細胞肺癌和轉移性結直腸癌。自獲得上市批准後,為了儘快幫助更多患者實現臨牀獲益,從宣佈獲批到首批發貨,博優諾®僅用了10天時間,並已相繼在全國多地開出首張處方。

博安生物首席執行官姜華表示:“阿斯利康在腫瘤治療領域和縣域市場深耕多年,擁有廣泛的創新資源和市場覆蓋。此次與阿斯利康的戰略合作是對博優諾®商業化網絡的重要補充和拓展。未來,我們將在多層級市場發揮各自的渠道優勢和患者人羣覆蓋優勢,並積極探討海外市場的合作機會,為更多患者提供高品質、可負擔的用藥選擇。”

阿斯利康全球執行副總裁、國際業務及中國總裁王磊表示:“一直以來,阿斯利康秉承‘以患者為中心’的理念,積極攜手社會各方資源,致力於讓更多縣域患者受益於先進的創新治療以及全病程、全生命週期的解決方案。博安生物是具備全產業鏈能力的綜合型生物製藥公司,擁有優秀的研發和生產團隊,是中國領先的本土企業,我們期待未來雙方緊密協作,將更多創新解決方案帶給縣域患者,為滿足中國不斷增長的健康需求而不懈努力。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account